Allergy Therapeutics (AGY)

 

AGY Share PerformanceMore

52 week high39.50 10/10/17
52 week low23.00 28/03/17
52 week change 0.10 (0.40%)
4 week volume2,141,657 27/01/18
price25.35
price date1519296247
close25.50

Latest NewsMore

Allergy Therapeutics to present on 7 March 2018 at the Shares and AJ Bell Spotlight Evening in London

If you are looking for some investment ideas for your ISA, then come along the Shares and AJ Bell Investor Evening in Lo...

Allergy completes recruitment in grass allergy study, results due ahead of expectations

Allergy Therapeutics plc announced Monday that recruitment has been completed in its grass allergy Phase II study with r...

Completion of recruitment in PQ Grass Ph II trial

RNS Number: 5209E Allergy Therapeutics PLC 12 February 2018 Allergy Therapeutics plc ("Allergy Therapeutics" or the "Group") Completion of recruitment in PQ Grass Phase II trial Trial running ahead of schedule with data now due in early H2 2018 12 February 2018 Allergy Therapeutics plc (AIM:AGY), the fully integrated specialty pharmaceutical group specia...

Hardman Research: Growth in a tough market

RNS Number: 7100D Allergy Therapeutics PLC 02 February 2018 Hardman Research: Growth in a tough market Growth in a tough market: AGY is a long-established specialist in the prevention, diagnosis and treatment of allergies. Pollinex Quattro (PQ) grass, the subcutaneous allergy immunotherapy (AIT), continues to gain market share despite being available in th...

Allergy Therapeutics first-half revenue rises 4.4%

Allergy Therapeutics said its was trading in line with its expectations, with first-half revenues to rise 4.4% to 42.2m. On con...

Trading Update

RNS Number: 4048D Allergy Therapeutics PLC 31 January 2018 Allergy Therapeutics plc ("Allergy Therapeutics" or the "Group") Trading Update Market share gains driving top line growth Strong cash position sustained by good performance. 31 January 2017 Allergy Therapeutics plc (AIM:AGY), the fully integrated specialty pharmaceutical group specialising in alle...

Holdings in Company

RNS Number: 5221B Allergy Therapeutics PLC 10 January 2018 TR-1: S tandard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii: Allergy The...

Allergy Therapeutics completes recruitment for clinical study

Allergy Therapeutics said recruitment of the group's phase III clinical trial with PQ Birch (PQBirch301) has been completed...

Fundamental DataMore

EPS-0.42
Dividend yield0 %

Latest discussion posts More

  • Re: Trading update looks good

    Things are looking good for AGY ,I just hope the margins are holding up , as there is no point in selling more products at reduced margins. BE HAPPY DAVE Allergy ...
    31-Jan-2018
    d gaser
  • Trading update

    Monday 29th (Tentative)
    29-Jan-2018
    Baffler
  • PQ Birch Phase III clinical tria

    09 January 2018 Allergy Therapeutics plc PQ Birch Phase III clinical trial completes recruitment 9 January 2018 Allergy Therapeutics plc (AIM:AGY), the fully integrated ...
    9-Jan-2018
    Totally Wired

Users' HoldingsMore

Users who hold Allergy Therapeutics also hold..

Codes & Symbols

ISINGB00B02LCQ05
SymbolsAGY, LSE:AGY, AGY.L, AGY:LN, LON:AGY, XLON:AGY

Join interactive investor

  • £22.50 fixed quarterly charge includes £22.50 in trading credits
  • £10 per trade or £6 for frequent traders
  • No % platform fees
  • £1 per trade for regular investment or dividend reinvestment

Open an account